BRCA2 and small cell lung carcinoma: Mutation of EGFR (7.4%), NOTCH1 (11.8%), TNFSF13B (6.4%) and BRCA2 (5.5%), as well as TERT amplification (10.9%) were restricted in TP53/RB1 co‐mutation samples, while FGFR1 amplification was more common in the SCLC patients with TP53 mutation alone (4/12 vs 2/93, P < 0.001) (Figure 2B).